EP14.04-01 BRCA-Associated Protein-1 (BAP1) Loss and Real-World Outcomes of Immune Checkpoint Inhibitor Therapy in Pleural Mesothelioma

Pleural mesothelioma is a rare malignancy with limited therapeutic options. Immunotherapy with ipilimumab plus nivolumab is an approved first-line treatment based on the results of CheckMate 743. BRCA-Associated Protein-1 (BAP1) is a tumor suppressor gene involved in DNA repair and is often altered in mesothelioma. This study aims to describe real-world outcomes with immunotherapy in patients with mesothelioma and the impact of BAP1 status on therapy response.